Research comparison
Survodutide vs Retatrutide
Survodutide and Retatrutide both carry the glucagon-receptor (GCGR) arm that GLP-1 mono-agonists lack. The difference is the GIP receptor: Retatrutide adds it, Survodutide does not. Because both share the GLP-1R + GCGR foundation, running them side by side isolates the single open question — what does GIPR co-agonism contribute on top of a GLP-1/glucagon backbone?
Short answer
Survodutide and Retatrutide both carry the glucagon-receptor (GCGR) arm that GLP-1 mono-agonists lack. The difference is the GIP receptor: Retatrutide adds it, Survodutide does not. Because both share the GLP-1R + GCGR foundation, running them side by side isolates the single open question — what does GIPR co-agonism contribute on top of a GLP-1/glucagon backbone?
Research-context summary: If the research question is “what does the glucagon arm add to GLP-1?” — Survodutide is the focused dual-agonist tool. If it is “what does GIP co-agonism add on top of GLP-1/glucagon?” — Retatrutide, run alongside Survodutide as the dual-agonist reference.
Use limitation: HALO comparison pages are for research context only; both materials are RUO and not for human or veterinary use.
| Survodutide | Retatrutide | |
|---|---|---|
| Receptor profile | GLP-1R + GCGR (dual) | GLP-1R + GIPR + GCGR (triple) |
| Class / identity | BI-456906; albumin-binding fatty-diacid | 39-aa tri-agonist scaffold (LY3437943); albumin-binding fatty diacid |
| Glucagon (GCGR) arm | Yes — hepatic lipolysis + energy expenditure | Yes — hepatic glucose output + BAT thermogenesis (UCP-1) |
| GIP (GIPR) arm | None | Full agonist |
| Differentiating lever | Glucagon arm on top of GLP-1 | GIP arm on top of GLP-1/glucagon |
| Primary research focus | Hepatic lipid metabolism, steatosis models | Energy expenditure, thermogenesis, multi-receptor metabolic models |
| Available sizes | 10 mg | Up to 100 mg |
Shared glucagon backbone, one receptor apart
Survodutide (BI-456906) is a dual GLP-1 receptor / glucagon receptor (GCGR) co-agonist. Retatrutide (LY3437943) is a triple agonist that adds full GIP-receptor activation to the same GLP-1R + GCGR pair. Both compounds therefore share the glucagon arm that distinguishes them from GLP-1 mono-agonists; the only receptor that separates them is GIPR. That makes the pair an unusually clean design for attributing an outcome specifically to GIP-receptor co-agonism.
What the GIP arm adds
The differentiating mechanism is GIP-receptor activation. On top of the shared GLP-1 (glucose-dependent insulin secretion, appetite suppression) and glucagon (hepatic lipolysis, increased energy expenditure) signals, Retatrutide layers a third incretin pathway studied for its contribution to insulin secretion and adipose handling. Survodutide holds the GLP-1/glucagon backbone constant without it. Researchers isolating the GIPR contribution can run Survodutide as the dual-agonist reference against Retatrutide as the triple agonist.
Different research emphasis
In practice the two compounds are positioned around different endpoints. Survodutide research concentrates on hepatic lipid metabolism and steatosis models, where the GLP-1/glucagon combination is the variable of interest. Retatrutide research spans broader energy-expenditure and thermogenesis questions, where the GCGR-driven brown-adipose activation and the added GIPR arm are studied together. Both rely on the same glycaemic-buffering principle: co-activated GLP-1R promotes glucose-dependent insulin release, so the glucagon arm proceeds without the hyperglycaemia native glucagon would cause.
Identity and handling
Both ship lyophilized at ≥98% HPLC purity with independent COA and carry albumin-binding fatty-diacids for extended research half-life — account for albumin sequestration in serum-containing media. Reconstitute in PBS pH 7.4 (cell culture) or sterile bacteriostatic water (in-vivo work); store −20 °C dry, 4 °C reconstituted ≤28 days. See the Survodutide and Retatrutide guides for full data.
Common comparison questions
What is the difference between Survodutide and Retatrutide?
Why run them side by side?
Do they target the same research questions?
Research use only. Both compounds are sold by HALO for in vitro and qualified laboratory research only. Not for human or veterinary use, diagnosis, or treatment.